Six patterns of drug-drug interactions

Psychosomatics

Volumn 44, Issue 3, 2003, Pages 255-258

  Armstrong, Scott C ^a,b   Cozza, Kelly L ^c,d   Sandson, Neil B ^e,f  

^a Tuality Forest Grove Hospital   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e SHEPPARD PRATT HEALTH SYSTEM   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; BUSPIRONE; CLOZAPINE; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FLUCONAZOLE; GLYCOPROTEIN P; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; IMMUNOSUPPRESSIVE AGENT; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PHENYTOIN; PLANT EXTRACT; PREDNISONE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; DEPRESSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ELECTROCARDIOGRAM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME SUBSTRATE; GRAFT REJECTION; HEART PALPITATION; HUMAN; LIVER METABOLISM; LIVER TRANSPLANTATION; MENTAL DISEASE; PSYCHOPHARMACOTHERAPY; SEIZURE; SIDE EFFECT; VERTIGO;

EID: 0037408443     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.44.3.255     Document Type: Article

References (27)

1. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI: Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15:125-131
2. Sawada Y, Ohtani H: [Pharmacokinetics and drug interactions of an tidepressive agents]. Nippon Rinsho 2001; 59:1539-1545 (Japanese)
3. Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ: Plasma bus pirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997; 62:348-354
4. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI: Tria zolam biotransformation by human liver microsomes in vitro: ef fects of metabolic inhibitors and clinical confirmation of a pre dicted interaction with ketoconazole. J Pharmacol Exp Ther 1996; 276:370-379
5. Serzone (nefazodone hydrochloride) Package Insert. Princeton, NJ, Bristol-Myers Squibb, Feb 2002
6. Kronbach T, Fischer V, Meyer UA: Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interac tions of cyclosporine with other drugs. Clin Pharmacol Ther 1998; 43: 630-635
7. Yokogawa K, Shimada T, Higashi Y, Itoh Y, Masue T, Ishizaki J, Asahi M, Miyamoto K: Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone. Biochem Pharmacol 2002; 63:777-783
8. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA: St John's wort induces he patic drug metabolism through activation of the pregnane X re ceptor. Proc Natl Acad Sci USA 2000; 97:7500-7502
9. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH: St John's wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000; 67:451-457
10. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J: St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002; 53-75-82
11. Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Klempnauer J: Drug interaction of St John's wort with cyclosporin (letter). Lancet 2000; 355:1912
12. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G: Acute heart transplant rejection due to Saint John's wort (letter). Lancet 2000; 355:548-549
13. DeVane CL, Nemeroff CB: Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40:509-522
14. Anderson GD: A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998; 32:554-563
15. Wong YW, Yeh C, Thyrum PT: The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol 2001; 21:89-93
16. Schwab M, Klotz U: Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001; 40:723-751
17. Michalets EL, Williams CR: Drug interactions with cisapride: clinical implications. Clin Pharmacokinet 2000; 39:49-75
18. Tiao GM, Martin J, Weber FL, Cohen RM, Hanto DW: Addisonian crisis in a liver transplant patient due to fluconazole withdrawal. Clin Transplant 1999; 13(1, part 1):62-64
19. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L: The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44:439-446
20. Schrenk D, Brockmeier D, Morike K, Bock KW, Eichelbaum M: A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur J Clin Pharmacol 1998; 53:361-367
21. Zevin S, Benowitz NL: Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 1999; 36:425-438
22. Myers JM: Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol 2001; 21:569-574
23. Ulrich S, Baumann B, Wolf R, Lehmann D, Peters B, Bogerts B, Título M: Therapeutic drug monitoring of clozapine and relapsea retrospective study of routine clinical data. Int J Pharmacol Ther 2003; 41:3-13
24. Van Der Wiede J, Steijns LS, Van Weelden MJ: The effect of smoking and cytochrome P4501A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003; 13:169-172
25. Zullino DF, Delessert D, Eap CB, Preisig M, Baumann P: Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002; 17:141-143
26. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH: The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60:636-644
27. Sindrup SH, Madsen C, Brosen K, Jensen TS: The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clin Pharmacol Ther 1999; 66:636-641